Skip to main content
. 2025 Aug 16;2025:3783469. doi: 10.1155/jdr/3783469

Table 2.

Comparison of baseline characteristics based on remission.

Parameter Remission ( N = 343) No remission ( N = 1110) Odds ratio 95% CI p value
Age at onset, N (%) 1.73 1.34–2.23 < 0.001
 > 40 years 227 (66.2%) 588 (53%)
 ≤ 40 years 116 (33.8%) 522 (47%)
Sex, N (%) 1.28 0.96–1.70 0.088
 Male 265 (77.3%) 806 (72.6%)
 Female 78 (22.7%) 304 (27.4%)
Diabetes duration, N (%) 0.27 0.21–0.35 < 0.001
 > 6 years 180 (52.5%) 889 (80.1%)
 ≤ 6 years 163 (47.5%) 221 (19.9%)
Medicine status, N (%) 0.33 0.23–0.48 < 0.001
 On OHA 286 (83.4%) 1041 (93.8%)
 Drug-naïve 57 (16.6%) 69 (6.2%)
Juice fasting, N (%) 1.08 0.85–1.38 0.269
 No 156 (45.5%) 528 (47.6%)
 Yes 187 (54.5%) 582 (52.4%)
BMI, median (IQR) and N (%)
 Median (IQR) 23.4 (1.9) 22.9 (2.3) < 0.001
 Normal (18.5–22.9 kg/m2) 136 (39.7%) 557 (50.2%) 1.53 1.19–1.96
 Overweight (23–24.9 kg/m2) 207 (60.3%) 553 (49.8%)
HOMA2%B, median (IQR) and N (%)
 Median (IQR) 46.8 (38) 34.1 (29.9) < 0.001
 Poor beta cell function (≤ 50) 183 (53.4%) 820 (73.9%) 0.40 0.31–0.52
 Good beta cell function (> 50) 160 (46.6%) 290 (26.1%)
HOMA2-IR, median (IQR) and N (%)
 Median (IQR) 0.8 (0.8) 0.8 (0.7) 0.154
 Insulin resistance (> 2) 22 (6.4%) 50 (4.5%) 0.68 0.41–1.15
 No insulin resistance (≤ 2) 321 (93.6%) 1060 (95.5%)
HbA1C, median (IQR) and N (%)
 Median (IQR) 6.8% (1.6) 7.6% (2.2) < 0.001
 Poor glycemic control (> 7%) 144 (42%) 725 (65.3%) 0.38 0.30–0.49
 Good glycemic control (≤ 7%) 199 (58%) 385 (34.7%)

Note: Data are presented as frequency and percentage for categorical variable and as median (IQR) and frequency (percentage) for continuous variable. Odds ratios, 95% CI, and p value reported using chi-square test.

Abbreviations: BMI, body mass index; CI, confidence interval; HbA1C, glycated hemoglobin; HOMA2%B, homeostatic model assessment of beta cell function; HOMA2-IR, homeostatic model assessment of insulin resistance; IQR, interquartile range; OHA, oral hypoglycemic agent.